Anti-Human IL5 Therapeutic Antibody (Mepolizumab) (CAT#: TAB-031)

Recombinant monoclonal antibody to Human IL5. Mepolizumab (proposed trade name Bosatria) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5), and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma which represents less than 5% of all asthma. IL-5 is a chemical messenger in the immune system that stimulates the growth of eosinophils. In eosinophilic asthma, eosinophils are present in the lungs. When mepolizumab was given to people with eosinophilic asthma, it eliminated eosinophils from the bloodstream,and reduced eosinophils in the lungs and bone marrow. Mepolizumab also reduced the number of asthma exacerbations, and reduced the need for corticosteroids.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Anti-interleukin (IL)-5 (mepolizumab) decreases β2 but not β1 integrin activation on blood eosinophils.

Reactivity of monoclonal antibody (A) KIM-127 (to the intermediate-activity state of β2 integrin), and (b) N29 (to the intermediate-activity state of β1 integrin) on blood eosinophils before (green) and after (blue) anti-IL-5 mepolizumab administration. Red, isotype control. A representative subject with mild allergic asthma from Ref. (34).

Johansson, M. W. . (2017). Eosinophil activation status in separate compartments and association with asthma. Frontiers in Medicine, 4, 75-.

Figure 2 Photomicrographs of esophageal biopsies before and after anti–IL-5 therapy. Biopsies from the distalesophagus before (A, B) and after (C, D) anti–IL-5 therapy (mepolizumab).

The photomicrographs have been selected to demonstrate representative well oriented (A, C) and typical biopsies with maximal tissue pathology (B, D). Note the presence of marked eosinophilic inflammation and epithelial hyperplasia before (week 8) and reduced eosinophilic inflammation and epithelial hyperplasia after (week 20) anti–IL-5. The photomicrographs were taken from patient number 4. Original magnification, 3400.

Osterman, & M. (2007). Anti-il-5 (mepolizumab) therapy for eosinophilic esophagitis. Yearbook of Gastroenterology, 2007, 169.


Specifications

  • Immunogen
  • Recombinant human IL5.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC
  • Trade name
  • bosatria
  • CAS
  • 196078-29-2
  • Generic Name
  • Mepolizumab
  • Biological Half-Life
  • 20 days
  • ATC Code
  • L04AC06
  • Related Disease
  • Asthma

Applications

  • Application Notes
  • The IL5 antibody has been reported in applications of Activ, IHC.

Target

  • Alternative Names
  • Mepolizumab;bosatria;196078-29-2;SB-240563;IL5;interleukin 5 (colony-stimulating factor, eosinophil);interleukin-5;B cell differentiation factor I;EDF;eosinophil differentiation factor;IL 5;interleukin 5;T cell replacing factor;TRF;T-cell replacing factor

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Mepolizumab.

See other products for "Mepolizumab"

Afuco™ Anti-IL5 ADCC Therapeutic Antibody (Mepolizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL5. Mepolizumab (proposed trade name Bosatria) is a humanized monoclonal antibody that recognizes interleukin-5 (IL-5), and is used to treat certain kinds of asthma and white blood cell diseases. Recent studies have concluded that mepolizumab may improve exacerbations in patients with severe eosinophilic asthma, an adult-onset asthma which represents less than 5% of all asthma. IL-5 is a chemical messenger in the immune system that stimulates the growth of eosinophils. In eosinophilic asthma, eosinophils are present in the lungs. When mepolizumab was given to people with eosinophilic asthma, it eliminated eosinophils from the bloodstream,and reduced eosinophils in the lungs and bone marrow. Mepolizumab also reduced the number of asthma exacerbations, and reduced the need for corticosteroids.

See other products for "IL5"


For Research Use Only. Not For Clinical Use.

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

© 2022 Creative BioLabs. All Rights Reserved
  • 0
  • 0

Cart